Top Biotech Companies With Best Stability & Growth (3,296)
Biotechnology is rewriting life as we know it, from the medicines we take, to the crops we grow, and the household goods that we rely on every day. But moving at the new speed of science requires better technology. Benchling’s mission is to unlock the power of biotechnology. The world’s most innovative biotech companies use Benchling’s R&D Cloud to power the...
Benchling's Top Stability & Growth Strengths
Strong Revenue Growth: Independent estimates point to continued ARR increases since 2022, with momentum remaining positive despite a slower pace than earlier hyper‑growth. Feedback suggests growth is ongoing and more disciplined rather than stagnating.
Product Line Growth: Company materials describe hundreds of new capabilities and AI‑powered tools launched through 2024–2025, alongside expanded modules and integrations. This sustained shipping cadence indicates continued investment and expansion of the platform’s surface area.
Strategic Partnerships: Named enterprise announcements include Novonesis adopting the platform across 1,500 scientists and an expanded collaboration with Moderna focused on AI‑driven research. These wins suggest ongoing enterprise adoption and deepening ties with marquee biopharma.
.png)
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products.
GRAIL's Top Stability & Growth Strengths
Strong Revenue Growth: Recent disclosures show rising total revenue and accelerating Galleri test volumes year over year, with both full‑year 2025 and early 2026 reporting continued momentum. Quarterly updates point to sustained double‑digit growth across revenue and volumes.
Strategic Partnerships: Announcements detail deeper channel integrations and access, including Epic EHR ordering, Quest connectivity, and collaborations with health systems, employers, and digital‑health platforms. International arrangements, such as a Samsung collaboration and a Canada launch, further extend reach.
Investor Backing & Capital Strength: The company secured additional financing in late 2025 and reports a cash position described as providing a multi‑year runway. Public company status post‑spin‑off offers direct access to capital markets to fund commercialization and regulatory efforts.
Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital Therapeutics™, Click delivers accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. Click’s treatments are defined by a commitment to applying technical and scientific rigor and patient-centric design to the development process. This...
Click Therapeutics's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Recent Series C and a $50M Series D tied to CT‑155, alongside strategic investment from Medidata/Dassault, indicate strong external support and added runway. Blue‑chip partners attaching capital to commercialization plans reinforce confidence in near‑term execution.
Product Line Growth: FDA clearance and U.S. launch of Rejoyn, FDA authorization for CT‑132, and Phase 3 success for CT‑155 advance the portfolio from development to marketed or near‑market assets. Acquired assets like AspyreRx and the Click SE initiative further broaden offerings.
Strategic Partnerships: Long‑standing collaborations with Otsuka, Boehringer Ingelheim, and Dassault Systèmes/Medidata underpin development, data capabilities, and commercialization pathways. These alliances suggest access to scale and expertise beyond a single company’s resources.
SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform...
SOPHiA GENETICS's Top Stability & Growth Strengths
Strong Revenue Growth: Recent disclosures highlight year-over-year revenue increases in 2025 and further growth in early 2026, with guidance pointing to continued double-digit expansion. Record analysis volumes and scaling usage underpin this top-line momentum.
Customer Loyalty & Retention: Net Dollar Retention improved and core genomics customers increased through 2025 into Q1 2026, indicating expanding spend and usage within the installed base. These trends suggest effective land-and-expand dynamics as newer applications drive deeper adoption.
Market Expansion: The company is adding a record number of new customers and expanding in the U.S., including large health-system wins and broader adoption of MSK-ACCESS/MSK-IMPACT. Rising platform analyses across regions signal broader geographic traction.
Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow. Through clinical and data science, we translate patient experiences into real-world evidence to improve treatment, inform policy, and advance research. Cancer is smart. Together, we can be smarter. Flatiron Health is an independent affiliate of the Roche Group.
Flatiron Health's Top Stability & Growth Strengths
Product Line Growth: In May 2026, the company launched Flatiron Telescope, an AI platform generating oncology insights in minutes, and highlighted 25+ ASCO 2026 research acceptances—signals of ongoing product and R&D investment.
Strategic Partnerships: Abbott integrated its precision oncology tests into OncoEMR on March 30, 2026, with similar prior integrations (e.g., Natera in 2025), indicating expanding in‑workflow partnerships across community oncology.
Market Expansion: Disclosures cite 5 million+ de‑identified patient records and multinational activity across the U.S., U.K., Germany, and Japan, alongside a tripled global oncology research network—evidence of growing geographic and dataset reach.
We bring together one of the world’s largest libraries of multimodal clinical and molecular data with a robust suite of AI tools to help physicians personalize care in real time, connect patients with therapies and clinical trials, and enable partners to accelerate discovery and development of new treatments. With ~8 million de-identified research records and 350+ petabytes of data, Tempus partners...
Tempus AI's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results and guidance show steep top-line expansion, with Q1 2026 revenue up year over year and full‑year 2026 outlook raised, indicating continued momentum.
Strategic Partnerships: Collaborations with major pharmaceutical companies and tools providers (e.g., AstraZeneca/Pathos, Merck, Gilead, Illumina, BMS) broaden product reach and support sustained demand.
Diversified Revenue Streams: Growth across Diagnostics and higher‑margin Data & Applications, alongside expanding offerings such as digital pathology and care pathway tools, indicates multiple engines contributing to scale.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Full-year 2025 total revenue increased with software up and drug discovery roughly doubling, and early 2026 showed continued expansion in underlying annual contract value with management guiding higher for the year.
Strategic Partnerships: Multiple new and expanded pharma collaborations and progress in co‑founded companies (e.g., an announced acquisition and positive clinical readouts) provide potential milestone and equity upside that supports growth.
Future-Ready Strategy: The accelerated shift from on‑premises licenses to hosted, ratable contracts aims to increase predictability, complemented by new offerings such as predictive toxicology and an agentic AI co‑scientist to deepen adoption.
Formation Bio is a tech-driven pharma company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes all aspects of drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data capture. Formation Bio acquires clinical-stage drugs from pharma and biotech and develops them faster and more efficiently, unlocking greater...
Formation Bio's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Evidence shows a $372M Series D in June 2024 led by a16z with Sanofi participation, one of the larger biotech financings that year. The capital is framed as fuel for acquiring or in-licensing assets and expanding AI capabilities, signaling strong investor confidence.
Strategic Partnerships: A three‑way collaboration with Sanofi and OpenAI announced in May 2024 to build AI software for drug development highlights high‑profile external alignment. Additional partnered activity, such as the 2025 Sanofi deal for gusacitinib, illustrates the company’s model in practice.
Product Line Growth: Since 2025 the portfolio expanded via in‑licensing and asset‑centric subsidiaries, including an anti‑CD226 mAb (IMIDomics), a miR‑124 activator (Kenmare Bio), and ex‑China rights to a CNS‑penetrant TYK2 inhibitor from Lynk. A planned Phase 1 start in H1 2026 underscores near‑term pipeline progression.
At Inato, we’re on a mission to accelerate the pace of medical innovation by bringing clinical research to each and every patient, regardless of who they are and where they live. Our platform, made to connect community-based research centers to trials across the globe, aims to create greater visibility, access, and engagement across a more diverse population of doctors and...
Inato's Top Stability & Growth Strengths
Market Expansion: Public disclosures show the site network rising from 5,500+ in September 2025 to 6,000+ across 50+ countries with 25+ sponsors by 2026, indicating steady expansion. Partnerships that add distribution—such as the RealTime eClinical tie-up covering 50+ networks and 2,000+ sites—further broaden reach.
Innovation-Driven Growth: In 2025 the company launched AI patient pre-screening and AI site-selection to accelerate enrollment and improve selection, with 2026 content highlighting added integrations and case studies. The CEO characterized these capabilities as the “biggest boost” to growth.
Investor Backing & Capital Strength: In March 2023 the company raised a $20M Series A2 to fund product innovation, international growth, and hiring. This capital base supports continued go-to-market and platform expansion.
Our purpose ensures that patients remain at the center of all we do. We live our purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to our medicines; using digital technologies to enhance our drug discovery and development, as well as patient outcomes; and leading the conversation to advocate for...
Pfizer's Top Stability & Growth Strengths
Product Line Growth: Company reports that launched and acquired products, including new oncology assets like Padcev, are contributing meaningful growth and momentum. Underlying non‑COVID revenue is increasing, with oncology and other recent launches adding to the base.
Cost & Operational Efficiency: Management indicates cost realignment and manufacturing programs are on track to deliver about $5.7B net savings by end‑2026, supporting margins and reinvestment. These measures provide capacity to fund launches and offset headwinds.
Future-Ready Strategy: The company highlights a sizable late‑stage pipeline and recent strategic acquisitions in oncology and obesity aimed at higher‑growth categories. Plans for numerous pivotal study starts in 2026 and continued pipeline investment position the business for longer‑term growth.
Help us shape the future of sports medicine! Breg provides premium, high-value sports medicine products and services that advance orthopedic patient care. From pioneering cold therapy products and innovative bracing to caring customer service and award-winning orthopedic practice solutions, Breg delivers a 360°customer experience unmatched in the industry. Breg is a company of Water Street Healthcare Partners. Founded in 1989, Breg offers...
AG Mednet, Inc. provides AI-powered clinical trial workflow management software. Their platform, Judi, streamlines processes for regulated research, aiming to accelerate execution from protocol to submission and enable clinical trial leaders to focus on developing breakthrough treatments.
Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with...
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Our goal is to discover, develop, manufacture, and commercialize transformative...
Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems. Adaptive’s proprietary immune profiling platform reveals and translates insights from our adaptive immune systems with unprecedented scale and precision. Working with drug developers, clinicians and academic researchers, we are applying these insights to develop...
Adaptive Biotechnologies Corp.'s Top Stability & Growth Strengths
Strong Revenue Growth: Revenue grew significantly year over year with continued quarterly momentum, led by rising clonoSEQ MRD volumes and management guidance for further expansion in 2026.
Cost & Operational Efficiency: Cash burn declined meaningfully and adjusted profitability metrics improved, with the MRD segment achieving positive contribution and initiatives underway to enhance margins and scale.
Investor Backing & Capital Strength: Analyst sentiment is predominantly positive with recent upgrades and targets above current levels, and the company enters 2026 with a solid cash position and a stated goal of positive free cash flow.
BioTAB Healthcare specializes in advanced, in-home compression therapy and manufactures medical equipment to treat lymphatic, wound, and circulatory disorders, aiming to improve patients' quality of life.
Axiom helps scientists eliminate molecular toxicity by providing the most accurate and affordable predictive models. Our proprietary dataset includes more than 100,000 molecules tested in pooled primary human liver cells, tens of thousands of molecules with pharmacokinetic measurements, and thousands of molecules with curated clinical outcome data. Axiom's AI models offer higher accuracy than advanced in vitro systems like 3d...
QuantHealth is an AI company conducting patient-centric drug simulations to accelerate and de-risk drug development. Over 90% of drugs in clinical development stage fail to reach the market, which accumulates to a $45B/year direct lost to the pharma and biotech industry. Our platform allows our pharma and biotech partners to rapidly run thousands of variations of their clinical trials to...
Ataraxis is an AI precision medicine company transforming cancer diagnostics and patient outcomes through the power of AI. We are addressing previously unsolvable problems in cancer prognosis and treatment selection through cutting-edge foundation models and multi-modal data. Our first clinically validated offering, Ataraxis Breast, is the world’s first AI-native prognostic/predictive test for breast cancer and provides greater accuracy than standard...
